| 4.16 0.1 (2.46%) | 09-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.13 | 1-year : | 6 |
| Resists | First : | 4.4 | Second : | 5.13 |
| Pivot price | 4.09 |
|||
| Supports | First : | 3.92 | Second : | 3.63 |
| MAs | MA(5) : | 4.03 |
MA(20) : | 4.02 |
| MA(100) : | 3.68 |
MA(250) : | 4.4  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 45.3 |
D(3) : | 45.2 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 6.51 | Low : | 2.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNKD ] has closed below upper band by 35.8%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.33 - 4.34 | 4.34 - 4.36 |
| Low: | 3.96 - 3.98 | 3.98 - 3.99 |
| Close: | 4.13 - 4.16 | 4.16 - 4.19 |
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Sat, 05 Sep 2026
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
Fri, 14 Aug 2026
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Thu, 13 Aug 2026
MannKind: New Approvals Majorly Increase MannKind's Prospects (NASDAQ:MNKD) - Seeking Alpha
Wed, 05 Aug 2026
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Sat, 25 Jul 2026
MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks - Yahoo Finance
Thu, 09 Jul 2026
MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 322 (M) |
| Shares Float | 298 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 57.2 (%) |
| Shares Short | 28,580 (K) |
| Shares Short P.Month | 28,190 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.22 |
| Profit Margin | -11.1 % |
| Operating Margin | -0.8 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 42.9 % |
| Gross Profit (p.s.) | 0.92 |
| Sales Per Share | 1.22 |
| EBITDA (p.s.) | 0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 40 (M) |
| PE Ratio | -27.74 |
| PEG Ratio | 4.3 |
| Price to Book value | -18.91 |
| Price to Sales | 3.39 |
| Price to Cash Flow | -166.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|